<scp>SGLT</scp> ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With <scp>MASH</scp> Cirrhosis and Type 2 Diabetes
SGLT-2 inhibitors are associated with a reduced risk of all-cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT-2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.
Authors
- Raffi Karagozian
- J.A. Porres
- Meena B. Bansal (ORCID: https://orcid.org/0000-0002-7501-2191)
- Carlos Alatorre
- Paul T. Kröner (ORCID: https://orcid.org/0000-0002-7361-7883)
- Donghyun Ko (ORCID: https://orcid.org/0000-0003-0592-490X)
- Do Han Kim
- F Lukens
- Luis M. Nieto
- Vincent L. Chen
- Donghee Kim
- Pedro Palacios Argueta
- Karn Wijarnpreecha
Institutions
- Tufts University (US)
- New York City Health and Hospitals Corporation (US)
- University of Arizona (US)
- Emory University (US)
- University of Phoenix (US)
- University of Michigan (US)
- Metropolitan Hospital Center (US)
- Jacksonville College (US)
- Bridgeport Hospital (US)
- Banner - University Medical Center Phoenix (US)
- Mayo Clinic Health System (US)
- Riverside Regional Medical Center (US)
- Universidad Francisco Marroquín (GT)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Liver International
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1111/liv.70490
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35